Tag: Biocon

The agreement allows the company to commercialize both its Denosumab biosimilars (Vevzuo® and Evfraxy®) in Europe starting December 2, 2025

Additional treatment options for the 38.4 million U.S. patients living with diabetes

Chairperson and Managing Director of Biocon welcomed the various initiatives made by the government

The Cover Story tracks the strides made by the Indian biotech industry towards sustainability goals. Special interview of Shivaji Dashrath Jadhav, Vice President & Head - EHS & Sustainability, Aragen Life Sciences. Expert Insights by Vikrant Agrawal, Co-founder, Care.fi and Rajeev Taneeja, Founder and CEO, Global Care. Special stories on bio-manufacturing, healthcare innovation and agri-foodtech.

This state-of-the-art facility is a significant addition to Burkert’s global value chain, aimed at meeting the growing demand in the region by producing components and system solutions

His loss resonates far beyond the corridors of industry, deeply touching the lives of millions he inspired

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan

Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success

Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics called upon the government to consider GST exemption for all cancer drugs to make cancer care more affordable for patients

A significant milestone for the company marking its entry into ophthalmology, a new therapeutic area in the United States